A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects with Mantle Cell Lymphoma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509353-31-00

Acronym

ACE-LY-106

Enrollment

Registered

2024-07-29

Start date

2016-09-05

Completion date

Unknown

Last updated

2025-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mantle Cell Lymphoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Poland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026